<DOC>
	<DOC>NCT01798667</DOC>
	<brief_summary>This study is designed to evaluate the efficacy and safety of DA-8031 and to decide the optimal dose of DA-8031 in male patients with premature ejaculation after oral administration on-demand. The investigators hypothesized that newly-developed DA-8031 would effect in delaying ejaculation in patients with premature ejaculation (PE). Design: Placebo-controlled, Randomized, Double-blind, Double-dummy, Parallel group, Fixed dose design</brief_summary>
	<brief_title>Clinical Trial to Evaluate the Efficacy and Safety of DA-8031 in Male Patients With Premature Ejaculation</brief_title>
	<detailed_description />
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Premature Ejaculation</mesh_term>
	<criteria>Male patients aged with premature ejaculation for more than 6 months. PEDT score ≥ 11 IIEFEF domain ≤ 21 Serum Creatinine ≥ 2.5 mg/dl AST, ALT &gt; 3*Upper limit of normal Subjects with hypotension(SBP/DBP&lt;90/50mmHg) or uncontrolled hypertension(SBP/DBP&gt;180/100mmHg) Subjects with chronic depression, psychiatric or schizophrenia, Subjects with alcohol, drug or substance abuse</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>